| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Kronos Longevity Research Institute, Phoenix, Arizona.
| Correspondence to: S. Mitchell Harman, MD, PhD, Kronos Longevity Research Institute, 2222 E Highland, Suite 220, Phoenix, AZ 85016 (e-mail: Harman{at}kronosinstitute.org). |
Typical age-related changes in body composition and function include loss of lean body and muscle mass, decreased muscle strength (Kallman et al, 1990) and fitness (Fleg and Lakatta, 1988), and loss of functional capacity (Fried et al, 1998). There is also an increase in total fat mass and percent body fat (Shimokata et al, 1989) accompanied by insulin resistance and a higher risk of type 2 diabetes (Fink et al, 1983; Kohrt et al, 1993), increased low-density lipoprotein (LDL) cholesterol, triglycerides, and fatty acids (Obisesan et al, 1997). Other changes in metabolism include negative calcium balance leading to decreased bone density and osteoporotic fractures (Wark, 1996), decreased protein synthesis, slower healing, and impaired immune system function (Scordamaglia et al, 1991). Predictably, in aging men, there also occur decreased frequency of and desire for sexual activity and a reduction in the number and quality of erections (Kaiser et al, 1988; Helgason et al, 1996; Morley et al, 2000). Behavioral and psychological manifestations of aging also include slower problem solving, lapses of memory, and increasing incidence of dementing illness.
It is unclear the extent to which alterations in hormone balance contribute to the changes enumerated above. Documented age-related changes in hormones in men include a decrease in circulating total T (Bremner and Prinz, 1983) and various measures of free or bioavailable T (Vermeulen and Kaufman, 1995), the latter decline described as steeper due to increases in circulating sex hormone binding globulin with age. The decreases in T have been observed to begin in the third decade and proceed at a more-or-less constant rate into extreme old age, whether measured cross-sectionally (Tenover et al, 1987) or longitudinally in the Baltimore Longitudinal Study of Aging (BLSA) (Figure 1A and B) and other study populations (Morley et al, 1997; Harman et al, 2001). There are also reductions in circulating growth hormone and insulin-like growth factor I (Ho et al, 1987; O'Connor et al, 1998) and a tendency for increased cortisol secretion, especially in response to stress (Arnetz, 1985; Van Cauter et al, 1996).
|
Each of the hormonal alterations mentioned above, occurring in young adults, can present a clinical picture having certain features in common with typical age-related changes in body composition and function. In particular, male hypogonadism is associated with loss of muscle mass and strength, increased total and (especially) truncal and visceral body fat (accompanied by mild insulin resistance), and reduced libido and erectile capacity. The relationship between impaired pituitary-gonadal axis function and diminished sexual response during aging is not fully delineated, but it has become clear recently that the decline in free/bioavailable T levels is sufficient to make a substantial fraction of men over the age of 65 hypogonadal, at least by standard criteria for serum hormone levels (Figure 2) (Harman et al, 2001).
|
The decline in sexual activity levels and erectile function with aging has been well documented in a number of studies. Martin (1977) followed total self-reported male "sexual outlet," including heterosexual and homosexual intercourse, masturbation, etc, in BLSA men and documented a profound decrease in rates of sexual activity with age. This change was accompanied by an expressed decrease in desire for sexual activity and an increase in the period men reported being comfortable without sex. These same BLSA men also reported a decrease in frequency of erections such that by age 70 and above, over 50% had no erections whatsoever. In a more recent study by Panser et al (1995), approximately 80% of men ages 40 to 49 reported adequate erectile function "all the time," whereas less than 20% of men ages 70 and older did so. Conversely, fewer than 5% of men ages 40 to 49 rated their erectile function as "little/none," whereas this level of deficiency occurred in nearly 40% of men ages 70 and older. In the same study, over 70% of the younger men reported desire for sex more than once weekly, but only about 15% of men over 70 had this level of libido. The number of men ages 40 to 49 with no interest in sex was less than 5%, but approximately 35% of men ages 70 and older expressed no desire for sexual activity. The decrease in erectile function with age has also been documented in a study by Feldman et al (1994) (Figure 3), in which approximately 50% of men ages 70 to 79 reported moderate or complete erectile dysfunction (ED) compared with 25% of men ages 40 to 49.
|
Although the decrease in free/bioavailable T levels with age has been shown in some studies to be correlated with the loss of muscle strength (Roy et al, 2002) and the decrease in bone mineral density (Scopacasa et al, 2000), even when age is adjusted for as a covariate, the finding of such associations does not prove causality. This is also true for the relationship of hormonal alterations to sexual function. In one study of BLSA men (Tsitouras et al, 1982) there did appear to be a weak relationship between total serum T levels and self-reported sexual activity, such that men over 60 in the lowest age-adjusted tertile for sexual outlet had lower serum T levels (P < .05) than those in the middle or upper tertiles (Figure 4). This relationship did not hold true for younger men. The concept that hormonal alterations underlie a significant fraction of age-related male sexual disability is further supported by data (Morley, personal communication) showing that the fraction of men complaining of ED who have an identifiable endocrine etiology increases from 43% in men less than 60 years of age to 83% of men more than 60 years of age.
|
An important step in establishing plausibility of a causal relationship between decreased T and altered erectile function and libido is the identification of biological mechanisms by which T-action alters each of these sexual functions. In the case of libido, it has long been known that exposure to T alters both brain function, and, in some species, structure (Xiao and Jordan, 2002; Cooke et al, 2003). There are both androgen and estrogen receptors on neurons in various areas of the brain, including those known to be involved in mediation of male sexual activity. It also appears, from experiments in a number of species, that T affects sexual behavior both directly and after local aromatization to estradiol in the brain (Vagell and McGinnis, 1997; Roselli and Chambers, 1999). In addition, a direct local role for T in erectile function is suggested by recent data derived from animal studies, which have shown that exposure to T increases, and deprivation of T decreases, the activity of constitutive NO synthase in the nonadrenergic, noncholinergic autonomic vascular nerve endings of the corpora cavernosa (Chamness et al, 1995; Zvara et al, 1995; Park et al, 1999). NO is an important mediator of the erectile response and directly activates guanyl cyclase in the vascular smooth muscle cells, leading to production of cyclic guanosine monphosphate (cGMP) from guanosine triphosphate. Increased cGMP relaxes smooth muscle, allowing the sinusoids of the corpora cavernosa to dilate, causing erection. Thus, the erectile response is augmented by T and impaired in its absence (Seo et al, 1999). The relevance of the above relationships to human physiology is likely but not proven at this point in time.
Final confirmation of the importance of T in mediating changes in sexual function with age await definitive data documenting the extent to which T replacement does or does not ameliorate this deficiency. Preliminary studies appear promising. In one study (Seo et al, 1999), 80% of older men (mean age 71) perceived their libido as improved after treatment with T, compared with about 8% receiving placebo. In another trial (Kunelius et al, 2002), 150 men ages 50 to 70 years were treated with placebo or dihydrotestosterone (DHT) (which is not aromatized to estrogen and hence is less likely to have effects at the central nervous system). Early morning erections improved transiently in the DHT group at 3 months of treatment, and the ability to maintain erection improved in the DHT group compared with the placebo group.
In summary, aging is associated with changes in body composition similar to those observed in men with hypogonadism. These changes include 1) loss of libido and decreased sexual function, 2) decreases in LBM, muscle strength, and endurance, 3) decreases in bone density, and 4) increases in body fat and insulin resistance
Total and free T levels also decrease with age in men. In older men,
circulating T or free T correlate positively with sexual function, LBM, muscle
strength,
O2max, and bone density
and correlate negatively with body fat. ED is frequently associated with low T
in older men. Relationships of endogenous androgen measures to clinical
outcome variables suggest that some deleterious age-related changes may be
caused by androgen depletion. Finally, T replacement appears to improve both
sexual desire and erectile capacity in some older men with low T levels.
Further studies of the risks and benefits of androgen replacement in aging
men, emphasizing clinical outcomes, especially ED and libido, are justified
and should further clarify these issues.
| References |
|---|
|
|
|---|
Bremner WJ, Prinz PN. A loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J Clin Endocrinol Metab. 1983; 56:1278-1281.[Abstract]
Chamness SL, Ricker DD, Crone JK, Dembeck CL, Maguire MP, Burnett AL, Chang TS. The effect of androgen on nitric oxide synthase in the male reproductive tract of the rat. Fertil Steril. 1995; 63:1101-1107.[Medline]
Cooke BM, Breedlove SM, Jordan CL. Both estrogen receptors and androgen receptors contribute to testosterone-induced changes in the morphology of the medial amygdala and sexual arousal in male rats. Horm Behav. 2003; 43:336-346.[Medline]
Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994; 151:54-61.[Medline]
Fink RI, Kolterman OG, Griffin J, Olefsky JM. Mechanisms of insulin resistance in aging. J Clin Invest. 1983; 71:1523-1535.
Fleg JL, Lakatta EG. Role of muscle loss in the age-associated
reduction in VO2 max. J Appl Physiol. 1988; 65:1147-1151.
Fried LP, Kronmal RA, Newman AB, Bild DE, Mittelmark MB, Polak JF,
Robbins JA, Gardin JM. Risk factors for 5-year mortality in older adults: the
Cardiovascular Health Study. JAMA. 1998; 279:585-592.
Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR.
Longitudinal effects of aging on serum total and free testosterone levels in
healthy men. Baltimore Longitudinal Study of Aging. J Clin
Endocrinol Metab. 2001; 86:724-731.
Helgason AR, Adolfsson J, Dickman P, Arver S, Fredrikson M,
Gothberg M, Steineck G. Sexual desire, erection, orgasm and ejaculatory
functions and their importance to elderly Swedish men: a population-based
study. Age Ageing. 1996; 25:285-291.
Ho KY, Evans WS, Blizzard RM, et al. Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations. J Clin Endocrinol Metab. 1987; 64:51-58.[Abstract]
Kaiser FE, Viosca SP, Morley JE, Mooradian AD, Davis SS, Korenman SG. Impotence and aging: clinical and hormonal factors. J Am Geriatr Soc. 1988; 36:511-519.[Medline]
Kallman DA, Plato C, Tobin J. The role of muscle loss in age-related decline in grip strength: a cross-sectional and longitudinal analysis. J Gerontol. 1990; 45:M82-M88.[Medline]
Kohrt WM, Kirwan JP, Staten MA, Bourey R, King DS, Holloszy JO. Insulin resistance in aging is related to abdominal obesity. Diabetes. 1993; 42:273-281.[Abstract]
Kunelius P, Lukkarinen O, Hannuksela ML, Itkonen O, Tapanainen JS.
The effects of transdermal dihydrotestosterone in the aging male: a
prospective, randomized, double blind study. J Clin Endocrinol
Metab. 2002; 87:1467-1472.
Martin CE. Sexual activity in the aging male. In: Money J, Musaph N, eds. Handbook of Sexology. New York, NY: Elsevier-North Holland; 1977 :813-824.
Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P, McCready D, Perry HM III. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism. 2000; 49:1239-1242.[Medline]
Morley JE, Kaiser FE, Perry HM III, et al. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism. 1997; 46:410-413.[Medline]
Obisesan TO, Toth MJ, Ades PA, Poehlman ET. Central markers of body fat distribution are important predictors of plasma lipids in elderly men and women. Exp Gerontol. 1997; 32:643-651.[Medline]
O'Connor KG, Tobin JD, Harman SM, Plato CC, Roy TA, Sherman SS, Blackman MR. Serum levels of insulin-like growth factor-I are related to age and not to body composition in healthy women and men. J Gerontol A Biol Sci Med Sci. 1998; 53:M176-M82.[Abstract]
Panser LA, Rhodes T, Girman CJ, Guess HA, Chute CG, Oesterling JE, Lieber MM, Jacobsen SJ. Sexual function of men ages 40 to 79 years: the Olmsted County Study of Urinary Symptoms and Health Status Among Men. J Am Geriatr Soc. 1995; 43:1107-1111.[Medline]
Park KH, Kim SW, Kim KD, Paick JS. Effects of androgens on the expression of nitric oxide synthase mRNAs in rat corpus cavernosum. BJU Int. 1999; 83:327-333.[Medline]
Roselli CE, Chambers K. Sex differences in male-typical copulatory behaviors in response to androgen and estrogen treatment in rats. Neuroendocrinology. 1999; 69:290-298.[Medline]
Roy TA, Blackman MR, Harman SM, Tobin JD, Schrager M, Metter EJ.
Interrelationships of serum testosterone and free testosterone index with FFM
and strength in aging men. Am J Physiol Endocrinol
Metab. 2002; 283:E284-E294.
Scopacasa F, Horowitz M, Wishart JM, Morris HA, Chatterton BE, Need AG. The relation between bone density, free androgen index, and estradiol in men 60 to 70 years old. Bone. 2000; 27:145-149.[Medline]
Scordamaglia A, Ciprandi G, Indiveri F, Canonica GW. The effect of aging on host defences. Implications for therapy. Drugs Aging. 1991; 1:303-316.[Medline]
Seo SI, Kim SW, Paick JS. The effects of androgen on penile reflex, erectile response to electrical stimulation and penile NOS activity in the rat. Asian J Androl. 1999; 1:169-174.[Medline]
Shimokata H, Tobin JD, Muller DC, Elahi D, Coon PJ, Andres R. Studies in the distribution of body fat: I. Effects of age, sex, and obesity. J Gerontol. 1989; 44:M67-M73.
Tenover JS, Matsumoto AM, Plymate SR, Bremner WJ. The effects of aging in normal men on bioavailable testosterone and luteinizing hormone secretion: response to clomiphene citrate. J Clin Endocrinol Metab. 1987; 65:1118-1126.[Abstract]
Tsitouras PD, Martin CE, Harman SM. Relationship of serum testosterone to sexual activity in healthy elderly men. J Gerontol. 1982; 37:288-293.[Medline]
Vagell ME, McGinnis MY. The role of aromatization in the restoration of male rat reproductive behavior. J Neuroendocrinol. 1997; 9:415-421.[Medline]
Van Cauter E, Leproult R, Kupfer DJ. Effects of gender and age on the levels and circadian rhythmicity of plasma cortisol. J Clin Endocrinol Metab. 1996; 81:2468-2473.[Abstract]
Vermeulen A, Kaufman JM. Ageing of the hypothalamo-pituitary-testicular axis in men. Horm Res. 1995; 43:25-28.[Medline]
Wark JD. Osteoporotic fractures: background and prevention strategies. Maturitas. 1996; 23:193-207.[Medline]
Xiao L, Jordan CL. Sex differences, laterality, and hormonal regulation of androgen receptor immunoreactivity in rat hippocampus. Horm Behav. 2002; 42:327-336.[Medline]
Zvara P, Sioufi R, Schipper HM, Begin LR, Brock GB. Nitric oxide mediated erectile activity is a testosterone dependent event: a rat erection model. Int J Impot Res. 1995; 7:209-219.[Medline]
This article has been cited by other articles:
![]() |
A. Armagan, N. N. Kim, I. Goldstein, and A. M. Traish Dose-Response Relationship Between Testosterone and Erectile Function: Evidence for the Existence of a Critical Threshold J Androl, July 1, 2006; 27(4): 517 - 526. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |